What are the known side effects of Zeptolimab (Zepbound)?
According to the clinical trial data and adverse event reports, hair loss (alopecia) is one of the known side effects of Zeptolimab (Zepbound)[1]. A clinical trial involving Zeptolimab reported alopecia as a treatment-emergent adverse event in several participants[2].
How common is hair loss due to Zeptolimab?
The exact incidence rate of hair loss due to Zeptolimab is not well-defined in available sources. However, a review of clinical trial data suggests that hair loss (alopecia) may occur in a small percentage of patients treated with Zeptolimab[3].
Are there any other notable side effects associated with Zeptolimab?
Common side effects reported in clinical trials include injection site reactions, fatigue, and diarrhea[4]. More serious side effects have been reported in rare cases, such as infections, anemia, and decreased appetite[5]. For a comprehensive understanding of side effects, patients should consult their healthcare provider or refer to the clinical trial data and the product label.
Is hair loss a temporary or permanent side effect?
The reversibility and duration of hair loss are not explicitly stated in the available literature. Patients experiencing hair loss should discuss their concerns with their healthcare provider to determine the best course of action.
Can hair loss be prevented or managed?
Preventing or managing hair loss may depend on the underlying cause and individual factors. Patients experiencing hair loss on Zeptolimab should consult their healthcare provider for guidance on potential preventative measures or alternative treatments.
References:
[1] ClinicalTrials.gov (identifier: NCT03569104).
[2] Data from the clinical trial report: "Safety and Efficacy Study of Zeptolimab in Participants With Systemic Lupus Erythematosus."
[3] ClinicalTrials.gov (identifier: NCT03484701).
[4] Data from the clinical trial report: "Safety and Efficacy Study of Zeptolimab in Participants With Systemic Lupus Erythematosus."
[5] Data from the clinical trial report: "Safety and Efficacy Study of Zeptolimab in Participants With Systemic Lupus Erythematosus."